Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 11Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5Radiotherapy 5dodecyl maltoside 4apaziquone 4tislelizumab 3Cystoscopy 3ALT-803 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1monalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Non-Muscle Invasive Bladder Neoplasms × hydroxycamptothecinum × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡